Go to
JCI Insight
Citations to this article
Paulina J. Paszkiewicz, … , Stanley R. Riddell, Dirk H. Busch
Published October 17, 2016
Citation Information: J Clin Invest. 2016;126(11):4262-4272. https://doi.org/10.1172/JCI84813.
Citation Information: J Clin Invest. 2016;126(11):4262-4272. https://doi.org/10.1172/JCI84813.
Abstract
The adoptive transfer of T cells that have been genetically modified to express a CD19-specific chimeric antigen receptor (CAR) is effective for treating human B cell malignancies. However, the persistence of functional CD19 CAR T cells causes sustained depletion of endogenous CD19+ B cells and hypogammaglobulinemia. Thus, there is a need for a mechanism to ablate transferred T cells after tumor eradication is complete to allow recovery of normal B cells. Previously, we developed a truncated version of the epidermal growth factor receptor (EGFRt) that is coexpressed with the CAR on the T cell surface. Here, we show that targeting EGFRt with the IgG1 monoclonal antibody cetuximab eliminates CD19 CAR T cells both early and late after adoptive transfer in mice, resulting in complete and permanent recovery of normal functional B cells, without tumor relapse. EGFRt can be incorporated into many clinical applications to regulate the survival of gene-engineered cells. These results support the concept that EGFRt represents a promising approach to improve safety of cell-based therapies.
Authors
Paulina J. Paszkiewicz, Simon P. Fräßle, Shivani Srivastava, Daniel Sommermeyer, Michael Hudecek, Ingo Drexler, Michel Sadelain, Lingfeng Liu, Michael C. Jensen, Stanley R. Riddell, Dirk H. Busch
Total citations by year
Citation information
Citations to this article (170)
| Title and authors | Publication | Year |
|---|---|---|
|
Somatic cell reprogramming for Parkinson's disease treatment
Li X, Fang K, Wang F |
Ibrain | 2025 |
|
Novel strategies to manage CAR-T cell toxicity.
Mulvey A, Trueb L, Coukos G, Arber C |
Nature reviews. Drug discovery | 2025 |
|
CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges
Golmohammadi M, Noorbakhsh N, Kavianpour M |
Advanced Biomedical Research | 2025 |
|
A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.
Svec M, Dötsch S, Warmuth L, Trebo M, Fräßle S, Riddell SR, Jäger U, D'Ippolito E, Busch DH |
Frontiers in immunology | 2024 |
|
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I, Kalafateli M, Triantos C |
International journal of molecular sciences | 2024 |
|
Signaling via a CD27-TRAF2-SHP-1 axis during naïve T cell activation promotes memory-associated gene regulatory networks
Jaeger-Ruckstuhl CA, Lo Y, Fulton E, Waltner OG, Shabaneh TB, Simon S, Muthuraman PV, Correnti CE, Newsom O, Engstrom IA, Kanaan SB, Bhise SS, Peralta JM, Ruff R, Price JP, Stull SM, Stevens AR, Bugos G, Kluesner MG, Voillet V, Muhunthan V, Morrish F, Olson JM, Gottardo R, Sarthy JF, Henikoff S, Sullivan LB, Furlan SN, Riddell SR |
Immunity | 2024 |
|
Effective and stable gene transduction in rhesus macaque iPSCs capable of T-lineage differentiation utilizing the piggyBac system
Tanaka M, Iwamoto Y, Wang B, Imai E, Yoshida M, Iriguchi S, Kaneko S |
Regenerative Therapy | 2024 |
|
In vivo manufacture and manipulation of CAR-T cells for better druggability.
Hou R, Zhang X, Wang X, Zhao X, Li S, Guan Z, Cao J, Liu D, Zheng J, Shi M |
Cancer metastasis reviews | 2024 |
|
Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
Dash CP, Sonowal D, Dhaka P, Yadav R, Chettri D, Satapathy BP, Sheoran P, Uttam V, Jain M, Jain A |
Frontiers in immunology | 2024 |
|
TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Minnie SA, Waltner OG, Zhang P, Takahashi S, Nemychenkov NS, Ensbey KS, Schmidt CR, Legg SR, Comstock M, Boiko JR, Nelson E, Bhise SS, Wilkens AB, Koyama M, Dhodapkar MV, Chesi M, Riddell SR, Green DJ, Spencer A, Furlan SN, Hill GR |
Science Immunology | 2024 |
|
Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8(+) T cell adoptive therapies in pre-clinical studies.
Wu MH, Valenca-Pereira F, Cendali F, Giddings EL, Pham-Danis C, Yarnell MC, Novak AJ, Brunetti TM, Thompson SB, Henao-Mejia J, Flavell RA, D'Alessandro A, Kohler ME, Rincon M |
Nature Communications | 2024 |
|
Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs
Zhong Y, Stauss HJ |
Cells | 2024 |
|
Synthetic Cells and Molecules in Cellular Immunotherapy
Lin H, Li C, Zhang W, Wu B, Wang Y, Wang S, Wang D, Li X, Huang H |
International journal of biological sciences | 2024 |
|
Finding Your CAR: The Road Ahead for Engineered T Cells.
Chen PH, Raghunandan R, Morrow JS, Katz SG |
The American Journal of Pathology | 2024 |
|
Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies
Srivastava S, Tyagi A, Pawar VA, Khan NH, Arora K, Verma C, Kumar V |
ImmunoTargets and Therapy | 2024 |
|
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Fang M, Allen A, Luo C, Finn JD |
Frontiers in Immunology | 2024 |
|
T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting
Anderson GS, Chapman MA |
Molecular Therapy | 2024 |
|
A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity
Kalinichenko SV, Ramadan L, Kruglova NA, Balagurov KI, Lukashina MI, Mazurov DV, Shepelev MV |
Biology | 2024 |
|
CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas.
Ren Y, Bao X, Feng M, Xing B, Lian W, Yao Y, Wang R |
Science China. Life sciences | 2024 |
|
Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters.
Park HB, Kim KH, Kim JH, Kim SI, Oh YM, Kang M, Lee S, Hwang S, Lee H, Lee T, Park S, Lee JE, Jeong GR, Lee DH, Youn H, Choi EY, Son WC, Chung SJ, Chung J, Choi K |
Nature communications | 2024 |
|
Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway
Adachi Y, Terakura S, Osaki M, Okuno Y, Sato Y, Sagou K, Takeuchi Y, Yokota H, Imai K, Steinberger P, Leitner J, Hanajiri R, Murata M, Kiyoi H |
Nature Communications | 2024 |
|
Evolving strategies for addressing CAR T-cell toxicities
Rankin AW, Duncan BB, Allen C, Silbert SK, Shah NN |
Cancer Metastasis Reviews | 2024 |
|
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala NJ, Wehrli M, Lee WH, Parker AL, Wiggin HR, Bouffard A, Dey A, Leick MB, Katsis K, Elder EL, Dolaher MA, Cook DT, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KM, Maus MV |
Blood | 2024 |
|
Preclinical development of a Chimeric Antigen Receptor (CAR) T-cell therapy targeting FGFR4 in rhabdomyosarcoma
Adam Cheuk, Meijie Tian, Jun Wei, Nityashree Shivaprasad, Steven Highfill, Berkley Gryder, David Milewski, G Tom Brown, Larry Moses, Hannah W. Song, Peter Azorsa, Jeetendra Kumar, Dina Schneider, Hsien-Chao Chou, Young Song, Katherine Masih, Yong Yean Kim, Brian Belyea, Corinne Linardic, Boro Dropulic, Rimas Orentas, Javed Khan |
Cell reports. Medicine | 2023 |
|
Editing a gateway for cell therapy across the blood-brain barrier.
Achón Buil B, Tackenberg C, Rust R |
Brain : a journal of neurology | 2023 |
|
Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression.
Dötsch S, Svec M, Schober K, Hammel M, Wanisch A, Gökmen F, Jarosch S, Warmuth L, Barton J, Cicin-Sain L, D'Ippolito E, Busch DH |
Proceedings of the National Academy of Sciences | 2023 |
|
Novel pathophysiological insights into CAR-T cell associated neurotoxicity
Genoud V, Migliorini D |
Frontiers in neurology | 2023 |
|
Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies.
Braun T, Schrader A |
Cancers | 2023 |
|
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
Fraessle SP, Tschulik C, Effenberger M, Cletiu V, Gerget M, Schober K, Busch DH, Germeroth L, Stemberger C, Poltorak MP |
Communications biology | 2023 |
|
Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
Wang H, Tang L, Kong Y, Liu W, Zhu X, You Y |
International journal of molecular sciences | 2023 |
|
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD Jr, Rook AH, Haun PL, Ruella M, Young RM, June CH |
Blood Advances | 2023 |
|
Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.
Bandara V, Foeng J, Gundsambuu B, Norton TS, Napoli S, McPeake DJ, Tyllis TS, Rohani-Rad E, Abbott C, Mills SJ, Tan LY, Thompson EJ, Willet VM, Nikitaras VJ, Zheng J, Comerford I, Johnson A, Coombs J, Oehler MK, Ricciardelli C, Cowin AJ, Bonder CS, Jensen M, Sadlon TJ, McColl SR, Barry SC |
Nature Communications | 2023 |
|
CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.
Yang P, Yu F, Yao Z, Ding X, Xu H, Zhang J |
Cancer Immunology, Immunotherapy | 2023 |
|
Intelligent tunable CAR-T cell therapy leads the new trend
Cheng J, Liu M, Zhang J |
Synthetic and Systems Biotechnology | 2023 |
|
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Marone R, Landmann E, Devaux A, Lepore R, Seyres D, Zuin J, Burgold T, Engdahl C, Capoferri G, Dell\u2019Aglio A, Larrue C, Simonetta F, Rositzka J, Rhiel M, Andrieux G, Gallagher DN, Schröder MS, Wiederkehr A, Sinopoli A, Do Sacramento V, Haydn A, Garcia-Prat L, Divsalar C, Camus A, Xu L, Bordoli L, Schwede T, Porteus M, Tamburini J, Corn JE, Cathomen T, Cornu TI, Urlinger S, Jeker LT |
Journal of Experimental Medicine | 2023 |
|
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Yang C, Nguyen J, Yen Y |
Journal of biomedical science | 2023 |
|
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.
Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, Dubrot J, Doench JG, Regev A, Vander Heiden MG, Maus MV, Manguso RT, Birnbaum ME, Hemann MT |
Nature Communications | 2023 |
|
Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development
Pérez-Amill L, Bataller À, Delgado J, Esteve J, Juan M, Klein-González N |
Frontiers in immunology | 2023 |
|
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”
Karpov DS, Sosnovtseva AO, Pylina SV, Bastrich AN, Petrova DA, Kovalev MA, Shuvalova AI, Eremkina AK, Mokrysheva NG |
International journal of molecular sciences | 2023 |
|
Building safety into CAR-T therapy.
Peters DT, Savoldo B, Grover NS |
Human Vaccines & Immunotherapeutics | 2023 |
|
Synthetic receptors for logic gated T cell recognition and function
S Simon, G Bugos, A Salter, S Riddell |
Current Opinion in Immunology | 2022 |
|
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
J Buechner, I Caruana, A Künkele, S Rives, K Vettenranta, P Bader, C Peters, A Baruchel, F Calkoen |
Frontiers in Pediatrics | 2022 |
|
Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer
K Teng, A Mansour, Z Zhu, Z Li, L Tian, S Ma, B Xu, T Lu, H Chen, D Hou, J Zhang, S Priceman, M Caligiuri, J Yu |
Gastroenterology | 2022 |
|
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
J Marvin-Peek, B Savani, O Olalekan, B Dholaria |
Cancers | 2022 |
|
Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation
S Radisch, M Poltorak, M Wagner, V Cletiu, C Radisch, I Treise, S Pann, A Weigt, S Artner, S Dreher, F Fechner, B Borjan, S Fraessle, M Effenberger, E Benke, G Navratil, N Hentschel, D Busch, T Schmidt, C Stemberger, L Germeroth |
Scientific Reports | 2022 |
|
Engineered cellular immunotherapies in cancer and beyond
A Finck, T Blanchard, C Roselle, G Golinelli, C June |
Nature Medicine | 2022 |
|
Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
Gille I, Claas FH, Haasnoot GW, Heemskerk MH, Heidt S |
Frontiers in immunology | 2022 |
|
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y |
Frontiers in immunology | 2022 |
|
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
Wang J, Shen K, Mu W, Li W, Zhang M, Zhang W, Li Z, Ge T, Zhu Z, Zhang S, Chen C, Xing S, Zhu L, Chen L, Wang N, Huang L, Li D, Xiao M, Zhou J |
Frontiers in immunology | 2022 |
|
Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
York J, Gowrishankar K, Micklethwaite K, Palmer S, Cunningham AL, Nasr N |
Frontiers in immunology | 2022 |
|
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M |
Journal for ImmunoTherapy of Cancer | 2022 |
|
B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
Chen GM, Melenhorst JJ, Tan K |
Science Translational Medicine | 2022 |
|
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
Ogasawara K, Lymp J, Mack T, Dell\u2019Aringa J, Huang C, Smith J, Peiser L, Kostic A |
Clinical Pharmacology & Therapeutics | 2022 |
|
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL |
Frontiers in immunology | 2022 |
|
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.
Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, Pacheco KZB, Malipatlolla M, Xu P, Hui JH, Murty T, Theruvath J, Mehta N, Yamada-Hunter SA, Weber EW, Heitzeneder S, Parker KR, Satpathy AT, Chang HY, Lin MZ, Cochran JR, Mackall CL |
Cell | 2022 |
|
Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors
Nie D, Guo T, Yue M, Li W, Zong X, Zhu Y, Huang J, Lin M |
Biomolecules | 2022 |
|
Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer
Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M |
Cancer Discovery | 2022 |
|
Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R, Hussein MS, He Y |
Expert Reviews in Molecular Medicine | 2022 |
|
Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy.
Balagopal S, Sasaki K, Kaur P, Nikolaidi M, Ishihara J |
Journal of Materials Chemistry B | 2022 |
|
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas.
Atar D, Mast AS, Scheuermann S, Ruoff L, Seitz CM, Schlegel P |
Biomedicines | 2022 |
|
Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
Ohta K, Sakoda Y, Tamada K |
International Journal of Hematology | 2022 |
|
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.
Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M |
Nature reviews. Clinical oncology | 2022 |
|
SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity.
Alcaina Y, Yang Y, Vedvyas Y, McCloskey JE, Jin MM |
Scientific Reports | 2022 |
|
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S |
Nature Biomedical Engineering | 2022 |
|
Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
Gu T, Hu K, Si X, Hu Y, Huang H |
2022 | |
|
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes.
Smole A |
Radiology and Oncology | 2022 |
|
B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA, Heimberger AB, Zhang A, Jing W, Ng JCK, Shinglot H, Seguin B, Salter AI, Riddell SR, Jensen MC, Gottschalk S, Moore PF, Torok-Storb B, Pollack SM |
Molecular cancer therapeutics | 2022 |
|
Modifying enzyme replacement therapy – A perspective
Schaible P |
Journal of Cellular and Molecular Medicine | 2022 |
|
Advances in Modular Control of CAR-T Therapy with Adapter-Mediated CARs
McCue AC, Yao Z, Kuhlman B |
Advanced Drug Delivery Reviews | 2022 |
|
The potential for Treg-enhancing therapies in transplantation
Steiner R, Pilat N |
Clinical & Experimental Immunology | 2022 |
|
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, Shademan B, Isazadeh A, Baradaran B |
Cancer Medicine | 2022 |
|
Stem Cell Therapy for Repair of the Injured Brain: Five Principles.
Rust R, Tackenberg C |
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry | 2022 |
|
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Shabaneh TB, Moffett HF, Stull SM, Derezes T, Tait LJ, Park S, Riddell SR, Lajoie MJ |
2022 | |
|
Insight into Next-Generation CAR Therapeutics: Designing CAR T Cells to Improve Clinical Outcomes
Emiliano Roselli, Rawan Faramand, Marco L. Davila |
Journal of Clinical Investigation | 2021 |
|
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival
J Julamanee, S Terakura, K Umemura, Y Adachi, K Miyao, S Okuno, E Takagi, T Sakai, D Koyama, T Goto, R Hanajiri, M Hudecek, P Steinberger, J Leitner, T Nishida, M Murata, H Kiyoi |
Molecular Therapy | 2021 |
|
T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges
D Haydar, J Ibañez-Vega, G Krenciute |
Frontiers in Oncology | 2021 |
|
Strategies for Dodging the Obstacles in CAR T Cell Therapy
PS Kozani, PS Kozani, F Rahbarizadeh, SK Nikkhoi |
Frontiers in Oncology | 2021 |
|
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
PS Kozani, PS Kozani, F Rahbarizadeh |
Frontiers in immunology | 2021 |
|
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun, X Xu, Y Li |
Journal of Experimental & Clinical Cancer Research | 2021 |
|
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
M Maucher, M Srour, S Danhof, H Einsele, M Hudecek, I Yakoub-Agha |
Cancers | 2021 |
|
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
E Moghanloo, H Mollanoori, M Talebi, S Pashangzadeh, F Faraji, F Hadjilooei, H Mahmoodzadeh |
Translational oncology | 2021 |
|
Current Status of CAR T Cell Therapy for Leukemias
K Harris, JL LaBelle, MR Bishop |
Current Treatment Options in Oncology | 2021 |
|
Combinatorial CAR design improves target restriction
H Köksal, P Dillard, A Juzeniene, G Kvalheim, EB Smeland, JH Myklebust, EM Inderberg, S Wälchli |
The Journal of biological chemistry | 2021 |
|
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
P Wendel, LM Reindl, T Bexte, L Künnemeyer, V Särchen, N Albinger, A Mackensen, E Rettinger, T Bopp, E Ullrich |
Cancers | 2021 |
|
Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
L Miao, Z Zhang, Z Ren, F Tang, Y Li |
Frontiers in immunology | 2021 |
|
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
B Moghimi, S Muthugounder, S Jambon, R Tibbetts, L Hung, H Bassiri, MD Hogarty, DM Barrett, H Shimada, S Asgharzadeh |
Nature Communications | 2021 |
|
Prodrugs and prodrug-activated systems in gene therapy
S Sheikh, D Ernst, A Keating |
Molecular Therapy | 2021 |
|
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
K Ogasawara, M Dodds, T Mack, J Lymp, J DellAringa, J Smith |
Clinical Pharmacokinetics | 2021 |
|
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
AM Tsimberidou, KV Morris, HH Vo, S Eck, YF Lin, JM Rivas, BS Andersson |
Journal of Hematology & Oncology | 2021 |
|
Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome
V Vavassori, E Mercuri, GE Marcovecchio, MC Castiello, G Schiroli, L Albano, C Margulies, F Buquicchio, E Fontana, S Beretta, I Merelli, A Cappelleri, PM Rancoita, V Lougaris, A Plebani, M Kanariou, A Lankester, F Ferrua, E Scanziani, C CottaRamusino, A Villa, L Naldini, P Genovese |
EMBO Molecular Medicine | 2021 |
|
Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy
L Xue, Y Yi, Q Xu, L Wang, X Yang, Y Zhang, X Hua, X Chai, J Yang, Y Chen, G Tao, B Hu, X Wang |
Cell Discovery | 2021 |
|
Cellular based treatment modalities for unresectable hepatocellular carcinoma
K Damiris, H Abbad, N Pyrsopoulos |
World journal of clinical oncology | 2021 |
|
Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors
B Kotter, F Engert, W Krueger, A Roy, WA Rawashdeh, N Cordes, B Drees, B Webster, N Werchau, D Lock, S Dapa, D Schneider, S Ludwig, C Rossig, M Assenmacher, J Mittelstaet, AD Kaiser |
Cancers | 2021 |
|
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
G Li, Z Zhang, L Cai, X Tang, J Huang, L Yu, G Wang, K Zhong, Y Cao, C Liu, Y Wang, A Tong, L Zhou |
OncoImmunology | 2021 |
|
How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
AJ Schoenfeld, RE O'Cearbhaill |
Cancer journal (Sudbury, Mass.) | 2021 |
|
Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments
DC Soler, A Kerstetter-Fogle, TS McCormick, AE Sloan |
Journal of Neuro-Oncology | 2021 |
|
[Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma]
J Ge, T T Zhao, C Y Wan, J Y Xia, S Y Guo, M X Yu, J Chen, Y Wang, K L Xu, Z Y Li |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2021 |
|
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma
LD Galva, L Cai, Y Shao, Y He |
Journal of genetics and genomics = Yi chuan xue bao | 2020 |
|
Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
CA Land, PR Musich, D Haydar, G Krenciute, Q Xie |
Journal of Translational Medicine | 2020 |
|
Current Advances in Osteosarcoma: Clinical Perspectives: Past, Present and Future
ES Kleinerman, R Gorlick |
2020 | |
|
CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy
D Huang, M Miller, B Ashok, S Jain, NA Peppas |
Advanced Drug Delivery Reviews | 2020 |
|
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
A Zhylko, M Winiarska, A Graczyk-Jarzynka |
Cancers | 2020 |
|
Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer
GV Kochneva, GF Sivolobova, AV Tkacheva, AA Gorchakov, SV Kulemzin |
Molecular Biology | 2020 |
|
Engineering Next-Generation CAR-T Cells for Better Toxicity Management
AE Andrea, A Chiron, S Bessoles, S Hacein-Bey-Abina |
International journal of molecular sciences | 2020 |
|
Orthotopic T-Cell Receptor Replacement—An “Enabler” for TCR-Based Therapies
K Schober, TR Müller, DH Busch |
Cells | 2020 |
|
A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers
B Motais, S Charvátová, M Hrdinka, M Šimíček, T Jelínek, T Ševčíková, Z Kořístek, R Hájek, JR Bagó |
Cancers | 2020 |
|
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
Z Hu |
Scientific Reports | 2020 |
|
convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
KE Landgraf, SR Williams, D Steiger, D Gebhart, S Lok, DW Martin, KT Roybal, KC Kim |
2020 | |
|
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
X Zhou, L Rasche, KM Kortüm, S Danhof, M Hudecek, H Einsele |
Frontiers in immunology | 2020 |
|
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells
M Ruella, DM Barrett, O Shestova, J Perazzelli, AD Posey, SJ Hong, M Kozlowski, SF Lacey, JJ Melenhorst, CH June, SI Gill |
Blood | 2020 |
|
Recent Advances in Allogeneic CAR-T Cells
DW Kim, JY Cho |
Biomolecules | 2020 |
|
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Z Wang, YJ Cao |
Frontiers in immunology | 2020 |
|
Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
W Yan, Z Liu, J Liu, Y Xia, K Hu, J Yu, YQ Li |
BioMed Research International | 2020 |
|
Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy C Yang, W Lei, H Xie, G Wu, J Wei, A Liang, W Qian |
OncoTargets and therapy | 2020 |
|
Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration
B Luo, Y Zhan, M Luo, H Dong, J Liu, Y Lin, J Zhang, G Wang, E Verhoeyen, Y Zhang, H Zhang |
Cell Death and Disease | 2020 |
|
Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir
L Patasic, J Seifried, V Bezler, M Kaljanac, IC Schneider, H Schmitz, C Tondera, J Hartmann, A Hombach, CJ Buchholz, H Abken, R König, K Cichutek |
Medical Microbiology and Immunology | 2020 |
|
Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo
SA Richman, LC Wang, EK Moon, UR Khire, SM Albelda, MC Milone |
Molecular Therapy | 2020 |
|
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
LJ Brandt, MB Barnkob, YS Michaels, J Heiselberg, T Barington |
Frontiers in immunology | 2020 |
|
Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours
K Hsu, S Middlemiss, F Saletta, S Gottschalk, GB McCowage, B Kramer |
Cancer Gene Therapy | 2020 |
|
A New Safety Approach Allowing Reversible Control of CAR T Cell Responses
AX Chen, IG House, PA Beavis, PK Darcy |
Molecular Therapy | 2020 |
|
Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
C Arndt, F Fasslrinner, LR Loureiro, S Koristka, A Feldmann, M Bachmann |
Cancers | 2020 |
|
Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene
MA Sellmyer, SA Richman, K Lohith, C Hou, CC Weng, RH Mach, RS OConnor, MC Milone, MD Farwell |
Molecular Therapy | 2020 |
|
Senolytic CAR T cells reverse senescence-associated pathologies
C Amor, J Feucht, J Leibold, YJ Ho, C Zhu, D Alonso-Curbelo, J Mansilla-Soto, JA Boyer, X Li, T Giavridis, A Kulick, S Houlihan, E Peerschke, SL Friedman, V Ponomarev, A Piersigilli, M Sadelain, SW Lowe |
Nature | 2020 |
|
Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity
T Sakai, S Terakura, K Miyao, S Okuno, Y Adachi, K Umemura, J Julamanee, K Watanabe, H Hamana, H Kishi, J Leitner, P Steinberger, T Nishida, M Murata, H Kiyoi |
Molecular Therapy — Oncolytics | 2020 |
|
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Tori N. Yamamoto, Ping-Hsien Lee, Suman Kumar Vodnala, Devikala Gurusamy, Rigel Kishton, Zhiya Yu, Arash Eidizadeh, Robert Eil, Jessica Fioravanti, Luca Gattinoni, James N. Kochenderfer, Terry J Fry, Bulent Arman Aksoy, Jeffrey Hammerbacher, Anthony C Cruz, Richard Siegel, Nicholas P. Restifo, Christopher A. Klebanoff |
Journal of Clinical Investigation | 2019 |
|
Treg cell-based therapies: challenges and perspectives
C Raffin, LT Vo, JA Bluestone |
Nature Reviews Immunology | 2019 |
|
CAR-T Cells: Future Perspectives
S Charrot, S Hallam |
2019 | |
|
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
Strohl, Naso |
Antibodies | 2019 |
|
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
L Springuel, C Lonez, B Alexandre, EV Cutsem, JP Machiels, MV Eynde, H Prenen, A Hendlisz, L Shaza, J Carrasco, JL Canon, M Opyrchal, K Odunsi, S Rottey, DE Gilham, A Flament, FF Lehmann |
BioDrugs | 2019 |
|
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
S Yu, M Yi, S Qin, K Wu |
Molecular Cancer | 2019 |
|
Switching on the green light for chimeric antigen receptor T-cell therapy
S Mardiana, J Lai, IG House, PA Beavis, PK Darcy |
IBMS BoneKEy | 2019 |
|
CAR T Cells: A Snapshot on the Growing Options to Design a CAR
A Holzinger, H Abken |
2019 | |
|
Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
M Mulazzani, SP Fräßle, I von Mücke-Heim, S Langer, X Zhou, H Ishikawa-Ankerhold, J Leube, W Zhang, S Dötsch, M Svec, M Rudelius, M Dreyling, M von Bergwelt-Baildon, A Straube, VR Buchholz, DH Busch, L von Baumgarten |
Proceedings of the National Academy of Sciences | 2019 |
|
A cetuximab-mediated suicide system in CAR-modified hematopoietic stem cells for cancer therapy
RL Kao, LC Truscott, TT Chiou, W Tsai, AM Wu, SN Oliveira |
Human Gene Therapy | 2019 |
|
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
MR Benmebarek, C Karches, B Cadilha, S Lesch, S Endres, S Kobold |
International journal of molecular sciences | 2019 |
|
Challenges and Opportunities for Childhood Cancer Drug Development
PJ Houghton, RT Kurmasheva, MM Gottesman |
Pharmacological reviews | 2019 |
|
Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model
MM Festag, J Festag, SP Fräßle, T Asen, J Sacherl, S Schreiber, MA Mück-Häusl, DH Busch, K Wisskirchen, U Protzer |
Molecular Therapy | 2019 |
|
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
CH Karches, MR Benmebarek, ML Schmidbauer, M Kurzay, R Klaus, M Geiger, F Rataj, BL Cadilha, S Lesch, C Heise, R Murr, J vom Berg, M Jastroch, D Lamp, J Ding, P Duewell, G Niederfellner, C Sustmann, S Endres, C Klein, S Kobold |
Clinical cancer research | 2019 |
|
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
R Kansal, N Richardson, I Neeli, S Khawaja, D Chamberlain, M Ghani, Q Ghani, L Balazs, S Beranova-Giorgianni, F Giorgianni, JN Kochenderfer, T Marion, LM Albritton, M Radic |
Science Translational Medicine | 2019 |
|
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
S Koristka, P Ziller-Walter, R Bergmann, C Arndt, A Feldmann, A Kegler, M Cartellieri, A Ehninger, G Ehninger, M Bornhäuser, MP Bachmann |
Cancer Immunology, Immunotherapy | 2019 |
|
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
K Mestermann, T Giavridis, J Weber, J Rydzek, S Frenz, T Nerreter, A Mades, M Sadelain, H Einsele, M Hudecek |
Science Translational Medicine | 2019 |
|
Conventional CARs versus modular CARs
A Feldmann, C Arndt, S Koristka, N Berndt, R Bergmann, MP Bachmann |
Cancer Immunology, Immunotherapy | 2019 |
|
Cytokine Release Syndrome: Current Perspectives H Murthy, M Iqbal, JC Chavez, MA Kharfan-Dabaja |
ImmunoTargets and Therapy | 2019 |
|
T cell engineering for adoptive T cell therapy: safety and receptor avidity.
D'Ippolito E, Schober K, Nauerth M, Busch DH |
Cancer Immunology, Immunotherapy | 2019 |
|
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach
AM Krackhardt, B Anliker, M Hildebrandt, M Bachmann, SB Eichmüller, DM Nettelbeck, M Renner, L Uharek, G Willimsky, M Schmitt, WS Wels, M Schüssler-Lenz |
Cancer Immunology, Immunotherapy | 2018 |
|
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
S Sun, H Hao, G Yang, Y Zhang, Y Fu |
Journal of Immunology Research | 2018 |
|
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
K Watanabe, S Kuramitsu, AD Posey, CH June |
Frontiers in immunology | 2018 |
|
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
AI Salter, MJ Pont, SR Riddell |
Blood | 2018 |
|
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions:
SY Lee, P Olsen, DH Lee, AL Kenoyer, LE Budde, S OSteen, DJ Green, S Heimfeld, MC Jensen, SR Riddell, OW Press, BG Till |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2018 |
|
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
S Srivastava, SR Riddell |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
|
Chimeric Antigen Receptor Therapy
CH June, M Sadelain |
New England Journal of Medicine | 2018 |
|
CAR T Cell Therapy for Neuroblastoma
RM Richards, E Sotillo, RG Majzner |
Frontiers in immunology | 2018 |
|
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
JN Brudno, JN Kochenderfer |
Blood Reviews | 2018 |
|
Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
C Rossig, S Kailayangiri, S Jamitzky, B Altvater |
Frontiers in Oncology | 2018 |
|
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, FM Schnorfeil, C Krupka, FS Lichtenegger, X Liu, P Kerbs, S Schneider, KH Metzeler, K Spiekermann, W Hiddemann, PA Greif, T Herold, M Sadelain, M Subklewe |
Leukemia | 2018 |
|
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
CA Pennell, JL Barnum, CS McDonald-Hyman, A Panoskaltsis-Mortari, MJ Riddle, Z Xiong, M Loschi, G Thangavelu, HM Campbell, MD Storlie, Y Refaeli, SN Furlan, MC Jensen, LS Kean, JS Miller, J Tolar, MJ Osborn, BR Blazar |
Molecular Therapy | 2018 |
|
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
EL Smith, M Staehr, R Masakayan, IJ Tatake, TJ Purdon, X Wang, P Wang, H Liu, Y Xu, SC Garrett-Thomson, SC Almo, I Riviere, C Liu, RJ Brentjens |
Molecular Therapy | 2018 |
|
Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
ZS Badieyan, SS Hoseini |
Archivum Immunologiae et Therapiae Experimentalis | 2018 |
|
Versatile CAR T-cells for cancer immunotherapy
F Chu, J Cao, SS Neelalpu |
WSPOLCZESNA ONKOL | 2018 |
|
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
S Viaud, JS Ma, IR Hardy, EN Hampton, B Benish, L Sherwood, V Nunez, CJ Ackerman, E Khialeeva, M Weglarz, SC Lee, AK Woods, TS Young |
Proceedings of the National Academy of Sciences | 2018 |
|
Efficient immunoaffinity chromatography of lymphocytes directly from whole blood
F Mohr, S Przibilla, F Leonhardt, C Stemberger, S Dreher, TR Müller, SP Fräßle, GP Schmidt, ML Kiene, H Stadler, DH Busch |
Scientific Reports | 2018 |
|
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
I Rivière, M Sadelain |
Molecular Therapy | 2017 |
|
Therapeutic T cell engineering
M Sadelain, I Rivière, S Riddell |
Nature | 2017 |
|
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
F Perna, SH Berman, RK Soni, J Mansilla-Soto, J Eyquem, M Hamieh, RC Hendrickson, CW Brennan, M Sadelain |
Cancer Cell | 2017 |
|
Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
D Bachmann, R Aliperta, R Bergmann, A Feldmann, S Koristka, C Arndt, S Loff, P Welzel, S Albert, A Kegler, A Ehninger, M Cartellieri, G Ehninger, M Bornhäuser, M Bonin, C Werner, J Pietzsch, J Steinbach, M Bachmann |
Oncotarget | 2017 |
|
Development of CAR T cells designed to improve antitumor efficacy and safety
JE Jaspers, RJ Brentjens |
Pharmacology & Therapeutics | 2017 |
|
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
N Mitwasi, A Feldmann, R Bergmann, N Berndt, C Arndt, S Koristka, A Kegler, J Jureczek, A Hoffmann, A Ehninger, M Cartellieri, S Albert, C Rossig, G Ehninger, J Pietzsch, J Steinbach, M Bachmann |
Oncotarget | 2017 |
|
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
A Feldmann, C Arndt, R Bergmann, S Loff, M Cartellieri, D Bachmann, R Aliperta, M Hetzenecker, F Ludwig, S Albert, P Ziller-Walter, A Kegler, S Koristka, S Gärtner, M Schmitz, A Ehninger, G Ehninger, J Pietzsch, J Steinbach, M Bachmann |
Oncotarget | 2017 |
|
Agents in Development for Childhood Acute Lymphoblastic Leukemia
KW Maloney, L Gore |
Pediatric Drugs | 2017 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)